InspireMD (NSPR) Stock Price, News & Analysis

Company Overview

InspireMD, Inc. is a medical device company focused on developing and commercializing products for the treatment of vascular disease, with an emphasis on reducing the risk of stroke during carotid artery procedures. The company’s principal technology is designed to provide embolic protection while supporting blood flow through narrowed arteries.

InspireMD’s primary product is the CGuard Embolic Prevention System, a carotid stent system that combines a self-expanding stent with the company’s proprietary MicroNet mesh. The mesh is intended to help trap and stabilize plaque that may otherwise break away during or after the procedure, potentially reducing the release of embolic material into the brain. The company has also developed related iterations of the CGuard platform, including CGuard Prime.

Founded in 2005 and headquartered in Tel Aviv, Israel, InspireMD has served international markets and pursued regulatory approval and commercialization of its products in additional regions, including the United States. Its products are intended for use by interventional specialists and hospitals treating patients with carotid artery disease. The company is led by President and Chief Executive Officer Marvin Slosman.

Key Stats

• Today's Range: $0.48 to $0.51
• 50-Day Range: $0.47 to $0.98
• 52-Week Range: $0.46 to $2.42
• Volume: 59,973 shs
• Average Volume: 142,029 shs
• Market Capitalization: $22.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.50
• Consensus Rating: Buy

InspireMD Stock Analysis - MarketRank™

InspireMD scored higher than 41% of companies evaluated by MarketBeat, and ranked 679th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

InspireMD has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

InspireMD has a consensus price target of $4.50, representing about 836.7% upside from its current price of $0.48.

Amount of Analyst Coverage

InspireMD has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for InspireMD are expected to grow in the coming year, from ($0.79) to ($0.73) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of InspireMD is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of InspireMD is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

InspireMD has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for NSPR.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InspireMD does not currently pay a dividend.

Dividend Growth

InspireMD does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added InspireMD to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, InspireMD insiders have not sold or bought any company stock.

Percentage Held by Insiders

24.98% of the stock of InspireMD is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

44.78% of the stock of InspireMD is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/12/2024
• Today: 10/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NYSE:NSPR
• CIK: 1433607
• Web: www.inspiremd.com
• Phone: 9728887766804
• Fax: N/A
• Employees: 127
• Year Founded: N/A

Price Target and Rating

• Average Price Target for InspireMD: $4.50
• High Price Target: $6.00
• Low Price Target: $3.00
• Potential Upside/Downside: +836.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19.92 million
• Net Margins: -413.96%
• Pretax Margin: -413.00%
• Return on Equity: -69.42%
• Return on Assets: -57.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.39
• Quick Ratio: 6.05

Sales & Book Value

• Annual Sales: $10.84 million
• Price / Sales: 2.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.83 per share
• Price / Book: 0.26

Miscellaneous

• Outstanding Shares: 46,489,000
• Free Float: 18,332,000
• Market Cap: $22.33 million
• Optionable: Optionable
• Beta: 0.84